Department of Critical Care Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
National Center for Trauma Medicine, Key Laboratory of Trauma and Neural Regeneration, Trauma Center, Peking University People's Hospital, Beijing, 100000, China.
J Ethnopharmacol. 2021 Aug 10;276:114199. doi: 10.1016/j.jep.2021.114199. Epub 2021 May 12.
Xuebijing injections originate from the traditional Chinese medicine (TCM) prescription XuefuZhuyu Decoction. It is composed of five Chinese herbal extracts; Carthami flos, Paeoniae radix rubra, Chuanxiong rhizoma, Salviae miltiorrhizae, and Angelicae Sinensis radix. The China Food and Drug Administration approved Xuebijing injections as a TCM preparation for the adjuvant treatment of sepsis.
This study aims to determine the effects of Xuebijing injections as an adjuvant to antibiotics for the treatment of renal microcirculatory dysfunction and renal inflammation in rats with sepsis.
The rats received a sham operation (Sham), sham operation followed by Xuebijign injection (Sxbj), cecal ligation and puncture (CLP), or CLP followed by Xuebijing injection (Cxbj). Renal microvascular perfusion in the cortex and oxygenation were assessed at different times after sepsis induction. Renal levels of interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α, and high mobility group box (HMGB)-1 were measured. Urinary TIMP-2 × IGFBP-7 and neutrophil gelatinase-associated lipocalin (NGAL) were measured as kidney biomarkers, and serum creatinine (SCr) was used to assess kidney injury. Tissue samples were stained for histologic evaluation.
The induction of sepsis increased local inflammation and decreased renal microvascular perfusion and oxygenation. Compared with the CLP group, the Cxbj group displayed improvements in microvascular perfusion and oxygenation (p < 0.05). The CLP group had significant increases in renal inflammatory biomarkers (IL-1β, IL-6, TNF-α, and HMGB-1; p < 0.05) and Xuebijing injection reduced the levels of these markers. The levels of urinary TIMP-2 × IGFBP-7, NAGL, and SCr were lower in the Cxbj group than in the CLP group (p < 0.05), and the CLP group had a higher Paller score than the Cxbj group (p < 0.05). However, the CLP and Cxbj groups had no significant difference in mortality.
This study into the early stages of sepsis in a rat model indicated that as an adjuvant therapy to antibiotics, Xuebijing injection improved renal perfusion and oxygenation, suppressed renal inflammation, and ameliorated kidney dysfunction. However, Xuebijing injection had no impact on mortality.
血必净注射液源自中药(TCM)方剂血府逐瘀汤。它由五种中药提取物组成;红花、赤芍、川芎、丹参和当归。中国食品药品监督管理局批准血必净注射液作为治疗脓毒症的中药制剂的辅助治疗。
本研究旨在确定血必净注射液作为抗生素辅助治疗脓毒症大鼠肾微循环功能障碍和肾炎症的效果。
大鼠接受假手术(Sham)、假手术加血必净注射液(Sxbj)、盲肠结扎和穿孔(CLP)或 CLP 后加血必净注射液(Cxbj)。在脓毒症诱导后不同时间评估皮质肾微血管灌注和氧合。测量肾组织中白细胞介素(IL)-1β、IL-6、肿瘤坏死因子(TNF)-α和高迁移率族蛋白(HMGB)-1的水平。尿 TIMP-2×IGFBP-7 和中性粒细胞明胶酶相关脂质运载蛋白(NGAL)作为肾生物标志物进行测量,血清肌酐(SCr)用于评估肾损伤。组织样本进行组织学评估。
脓毒症的诱导增加了局部炎症并降低了肾微血管灌注和氧合。与 CLP 组相比,Cxbj 组的微血管灌注和氧合得到改善(p<0.05)。CLP 组肾炎症生物标志物(IL-1β、IL-6、TNF-α和 HMGB-1)显著增加,血必净注射液降低了这些标志物的水平。Cxbj 组尿 TIMP-2×IGFBP-7、NAGL 和 SCr 水平低于 CLP 组(p<0.05),CLP 组的 Paller 评分高于 Cxbj 组(p<0.05)。然而,CLP 和 Cxbj 组在死亡率方面没有差异。
这项关于脓毒症早期阶段的大鼠模型研究表明,作为抗生素的辅助治疗,血必净注射液改善了肾灌注和氧合,抑制了肾炎症,改善了肾功能障碍。然而,血必净注射液对死亡率没有影响。